The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Official Title: Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Study ID: NCT04519905
Brief Summary: So far, there is no specific clinical guideline for elderly patients (\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx) or the chemoradiotherapy group (50.4Gy/28Fx;Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.
Detailed Description: Up to now, definitive radiotherapy was major treatment plan for elderly ESCC patients. However, whether elective elderly patients can obtain survival benefits through chemoradiotherapy is not clear. Thus we design the clinical trail to answer the question. Three hundred and twenty elderly patients with ESCC would be recruited. There are two stratification factors including 80 years old and lymph node metastasis. The patients in the chemoradiotherapy group were treated with paclitaxel (45mg/m2) and carboplatin (AUC=2) one cycle per week for five cycles.The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival. The life quality questionnaire included QlQ-C30 and OES-18.
Minimum Age: 76 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Huadong Hospital, Shanghai, Shanghai, China
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
Name: Kuaile Zhao, doctor
Affiliation: Fudan University
Role: STUDY_CHAIR
Name: Xiangpeng Zheng, doctor
Affiliation: Huadong Hospital
Role: PRINCIPAL_INVESTIGATOR